Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D
Newsroom
NEWS
All our latest news
Servier receives a positive CHMP opinion for ONIVYDE® in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as first line therapy in patients with metastatic pancreatic adenocarcinoma.
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma